ArticleFrontiers in immunology2026
Novel application for the JAK inhibitor baricitinib in the treatment of Vogt-Koyanagi-Harada disease: a prospective cohort study.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to prospectively evaluate the clinical efficacy and safety of baricitinib, a selective Janus kinase (JAK)1/JAK2 inhibitor, in the treatment of patients with Vogt-Koyanagi-Harada (VKH) disease. Design: The study was designed as a prospective, open-label, longitudinal, single-center cohort study. Methods: We enrolled 38 patients (76 eyes) with VKH disease (including both initial-onset and recurrent/chronic cases) at Tongji Hospital, Wuhan, China, between 2022 and 2024. Patients were assigned to one of two treatment protocols based on disease severity and prior treatment history: group A received oral baricitinib (4 mg/day) combined with systemic methylprednisolone, and group B received oral baricitinib monotherapy. Clinical assessments were performed at baseline and at 1, 3, 6, 12, and 18 months. Primary outcome measures included best-corrected visual acuity (BCVA), anterior chamber (AC) cell and flare grades, subfoveal choroidal thickness (SFCT), subretinal fluid (SRF) height, and angiographic inflammatory scores (fluorescein angiography [FA]/indocyanine green angiography [ICGA]). Secondary outcomes included quality-of-life scores (25-item version of the Visual Function Questionnaire [VFQ-25], SF-36), adverse drug reactions (ADRs), and recurrence rates. Results: The cohort included 44 eyes with early-stage (initial-onset) and 32 eyes with late-stage (recurrent) VKH disease (mean age: 43.1 years ± 12.3 years; follow-up: 6-18 months). Inflammation control was achieved in all patients in both groups. In group A, the combination therapy led to rapid resolution of inflammation. In group B (monotherapy), significant improvements were observed from baseline to the final visit, including improved BCVA (0.12 to 0.68, Conclusion: This study demonstrates that baricitinib is a promising therapeutic option for both early- and late-stage VKH disease. It effectively controls choroidal inflammation, improves visual function, and allows for a substantial reduction in corticosteroid burden with a favorable safety profile. Clinical trial registration: http://www.chictr.org.cn, identifier ChiCTR2100048030.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.